PURPOSE: The aim of our study was to evaluate the pharmacology of vorapaxar (SCH 530348), an oral PAR-1 antagonist, in healthy volunteers. METHODS AND RESULTS: In two randomized, placebo-controlled studies, subjects received either single ascending doses of vorapaxar (0.25, 1, 5, 10, 20, or 40 mg; n = 50), multiple ascending doses of vorapaxar (1, 3, or 5 mg/day for 28 days; n = 36), a loading dose (10 or 20 mg) followed by daily maintenance doses (1 mg) for 6 days (n = 12), or placebo. Single 20- and 40-mg doses of vorapaxar completely inhibited thrombin receptor activating peptide (TRAP)-induced platelet aggregation (>80% inhibition) at 1 h and sustained this level of inhibition for ≥72 h. Multiple doses yielded complete inhibition on Day 1 (5 mg/day) and Day 7 (1 and 3 mg/day). Adverse events were generally mild, transient, and unrelated to dose. CONCLUSION:Vorapaxar provided rapid and sustained dose-related inhibition of platelet aggregation without affecting bleeding or clotting times.
RCT Entities:
PURPOSE: The aim of our study was to evaluate the pharmacology of vorapaxar (SCH 530348), an oral PAR-1 antagonist, in healthy volunteers. METHODS AND RESULTS: In two randomized, placebo-controlled studies, subjects received either single ascending doses of vorapaxar (0.25, 1, 5, 10, 20, or 40 mg; n = 50), multiple ascending doses of vorapaxar (1, 3, or 5 mg/day for 28 days; n = 36), a loading dose (10 or 20 mg) followed by daily maintenance doses (1 mg) for 6 days (n = 12), or placebo. Single 20- and 40-mg doses of vorapaxar completely inhibited thrombin receptor activating peptide (TRAP)-induced platelet aggregation (>80% inhibition) at 1 h and sustained this level of inhibition for ≥72 h. Multiple doses yielded complete inhibition on Day 1 (5 mg/day) and Day 7 (1 and 3 mg/day). Adverse events were generally mild, transient, and unrelated to dose. CONCLUSION:Vorapaxar provided rapid and sustained dose-related inhibition of platelet aggregation without affecting bleeding or clotting times.
Authors: Deepak L Bhatt; Keith A A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Danielle M Brennan; Liz Fabry-Ribaudo; Joan Booth; Eric J Topol Journal: N Engl J Med Date: 2006-03-12 Impact factor: 91.245
Authors: Richard C Becker; David J Moliterno; Lisa K Jennings; Karen S Pieper; Jinglan Pei; Alan Niederman; Khaled M Ziada; Gail Berman; John Strony; Diane Joseph; Kenneth W Mahaffey; Frans Van de Werf; Enrico Veltri; Robert A Harrington Journal: Lancet Date: 2009-03-14 Impact factor: 79.321
Authors: Teddy Kosoglou; Walter K Kraft; Bharath Kumar; Paul Statkevich; Fengjuan Xuan; Lei Ma; Lisa K Jennings; James E Schiller; Ronald B Langdon; David L Cutler Journal: Eur J Clin Pharmacol Date: 2012-02-08 Impact factor: 2.953
Authors: Omozuanvbo Aisiku; Christian G Peters; Karen De Ceunynck; Chandra C Ghosh; James R Dilks; Susanna F Fustolo-Gunnink; Mingdong Huang; Chris Dockendorff; Samir M Parikh; Robert Flaumenhaft Journal: Blood Date: 2015-01-13 Impact factor: 22.113
Authors: Ping Zhang; András Gruber; Shogo Kasuda; Carey Kimmelstiel; Katie O'Callaghan; Daniel H Cox; Andrew Bohm; James D Baleja; Lidija Covic; Athan Kuliopulos Journal: Circulation Date: 2012-06-15 Impact factor: 29.690